Targets › SQLE
1 program from 1 company in 1 trial: 1 Phase 2; Oncology; next expected readout Feb 2028.
Catalyzes the stereospecific oxidation of squalene to (S)-2,3-epoxysqualene, and is considered to be a rate-limiting enzyme in steroid biosynthesis. (UniProt, Q14534)
Open in Phaseline: the race on SQLE, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Swiss Cancer Institute | Terbinafine Squalene epoxidase (SQLE) inhibitor | SQLE | Phase 2 | Recurrent Prostate Cancer | Feb 2028 |
Recurrent Prostate Cancer (1)
small molecule (1)
Swiss Cancer Institute (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.